FDA Alert - AmEx Pharmacy Issues Voluntary Nationwide Recall for one Lot of Bevacizumab 1.25mg/0.05m

By :

New Ebola Vaccine for Exposure Risk

AmEx Pharmacy is voluntarily recalling one Lot of Bevacizumab 1.25mg/0.05mL 31G Injectable to the consumer/user level. The Monoject Syringe of this product may become difficult to express, and when additional force is applied, while the needle is in the eye, may cause injury to the patient. The additional force needed to express the drug product could potentially result in damage to the eye while the needle is in the eye. To date, AmEx Pharmacy has received three reports associated with the Lot being recalled as either being difficult to express, two of which, resulted in an Adverse Drug Event. The product is used for Wet Age-related Macular Degeneration and Diabetic Retinopathy. It is individually wrapped and labeled in a Tyvek pouch which is then placed in a labeled amber bag to protect from light. The affected Lot ofBevacizumab 1.25mg/0.05m 3 lG Injectable is 190212AB, BUD 5/13/2019. The product can be identified by referencing the Lot number 190212AB, which prominently appears on all labeling. This specific Lot was distributed nationwide to ophthalmologist clinics in the following states: PA, IL, TX, WI, KS, TN, IN, & AZ. AmEx Pharmacy is notifying its consignees by telephone and overnight mail and is arranging for return/replacement of all recalled product. Administering physicians that have product which is being recalled should stop use, remove from inventory and return to AmEx Pharmacy. Consumers with questions regarding this recall can contact AmEx Pharmacy at (800) 644 - 9431 or by email at pharmacist@amexpharmacy.com during normal business hours Monday through Friday 9:00a.m. - 6:00p.m, EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to being administered this drug product. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. ( source : online news feed ) #FDA #Alert
Rate UsDon’t love itNot greatGoodGreatLove itRate Us
Your opinion
arrow&v
arrow&v

PHAF Team

FDA action against 14 companies for selling illegal cancer treatments

PHAF Team

Patient Receiving Ocrelizumab may be associated with PML

PHAF Team

Drug Alert : 60 drugs found substandard

PHAF Team

Torrent Pharmaceuticals Limited - Recall of Losartan Potassium Tablets

PHAF Team

After Fortis - Now Medanta hospital in Gurgaon charges massive Rs 16 lakh; 7-year-old dies

PHAF Team

FDA Alert - Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and

© 2019 PHAF  || All rights reserved

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon

Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.